



Federal Innovation Connections Grant Awarded to Support Drug Discovery

Highlights

- **Federal Innovation Connections grant received for \$50,000 from AusIndustry**
- **Awarded to part support research into new drug development**
- **Deepening collaboration with UNSW Sydney**

Sydney 6 December 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** has been awarded an Innovation Connections grant for \$50,000, to part fund research into new therapies for the treatment of inflammatory diseases.

Innovation Connections is a service delivered by CSIRO as part of the Australian Government's Entrepreneurs' Programme, which drives business growth and competitiveness by supporting business improvement and research collaboration in targeted growth sectors, and the commercialisation of novel products, processes and services.

The non-dilutive funding, alongside a company contribution, will fully fund the work of a postdoctoral medicinal chemist, under the supervision of Professor Naresh Kumar at the UNSW Sydney campus, to synthesise novel drug candidates and optimise their design. This activity will deepen Noxopharm's relationship with the UNSW team and complement other work already underway.

The grant is the third recently awarded to Noxopharm, and reflects the company's strategy of seeking non-dilutive grant funding that supports its pipeline while validating its scientific approach and partnerships with leading research institutions.

Noxopharm CEO Dr Gisela Mautner said: "We are strong believers in a collaborative approach to research and development, and engaging with leading experts in their fields. This grant will help us continue our work with the outstanding scientists at UNSW. Our science-driven strategy means we are constantly exploring new ways to build our drug discovery pipeline and identify new molecules with significant potential for treating life-threatening diseases."

"We are grateful for the support we have received from UNSW and AusIndustry in putting this application together, and also want to emphasise the importance of the Entrepreneurs' Programme for businesses like ours, especially regarding the identification of medical technologies and pharmaceuticals as a key growth area for the Australian economy."

Professor Kumar from UNSW said: "Finding new therapies for inflammatory diseases is a high priority for the research community, and this project will help support our work as we seek promising new drug candidates for further development."

-ENDS-



About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.